

Fig. 2. Effect of GLAST on glutamate uptake activity and Na^+ accumulation in Müller glial cells. (A) Na^+ imaging of Müller cells treated with 3 mM glutamate. Fluorescence images are shown in pseudocolor, with blue and red representing the lowest and highest intensities, respectively. The indicated times represent the number of seconds after initial application of glutamate. Glutamate-induced Na^+ accumulation was increased in the WT Müller cells, but not in the GLAST KO Müller cells. Scale bar: 20 μm. (B) Quantification of Na^+ accumulation in response to the glutamate stimulation in Müller cells from WT and GLAST KO mice. Müller cells were loaded with the CoroNa Green Na^+ indicator and stimulated with a bath-application of 3 mM glutamate. Pretreatment with 50 ng/ml of IL-1 for 24 h significantly suppressed Na^+ accumulation in Müller cells from the WT, but not from the GLAST KO mice. The data are presented as means ± standard errors of 9–15 cells for each group from three independent cultures. $^*p < 0.05$. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.).

reported [5,7], GLAST is expressed in Müller glial cells (Fig. 1A) and EAAC1 is mainly expressed in RGCs and amacrine cells (Fig. 1C). These immunoreactivities were not observed in GLAST and EAAC1 KO mice (Fig. 1B and D). We next performed immunoblot analysis with neural retinas. GLAST and EAAC1 KO mice showed no compensatory upregulation of EAAC1 and GLAST, respectively (Fig. 1E).

The glutamate uptake by GLAST is important for retinal neuroprotection *in vivo* [5,7], and we recently reported that IL-1 increases glutamate uptake in Müller cells [11]. Consistent with the previous findings, pretreatment with IL-1 (50 ng/ml) for 12 and 24 h significantly increased the glutamate uptake activity in WT Müller cells, which we measured by monitoring the uptake of L-[^{3}H]glutamate (Fig. 1F). Since the IL-1 receptor in the mouse retina was co-expressed with GLAST in Müller cells [11], these results suggest strongly an interaction between GLAST and IL-1 receptor activation on glutamate uptake in Müller cells. However, retinal glia may express EAAC1 and GLT-1 as well as GLAST [8]. Therefore, we explored the relationship between IL-1 stimulation and the activation of glutamate transporters using Müller cells prepared from the GLAST and EAAC1 KO mice. The capacity of glutamate uptake was severely impaired in the GLAST KO Müller cells (0.9 ± 0.1 nmol/mg protein/min), but was normal in the EAAC1 KO Müller cells (2.6 ± 0.1 nmol/mg protein/min), compared with the WT Müller cells (2.6 ± 0.2 nmol/mg protein/min; Fig. 1F). We next stimulated these Müller cells with 50 ng/ml of IL-1 for the indicated time periods prior to the detection of glutamate uptake. Pretreatment with IL-1 for 12 and 24 h significantly increased glutamate uptake in the WT (3.6 ± 0.1 and 3.8 ± 0.2 nmol/mg protein/min) and EAAC1 KO Müller cells (3.5 ± 0.3 and 3.8 ± 0.1 nmol/mg protein/min). Interestingly, IL-1 also stimulated glutamate uptake in the GLAST KO Müller cells, though modestly (1.7 ± 0.1 and 1.8 ± 0.1 nmol/mg protein/min), where the basal glutamate uptake in the GLAST KO Müller cells was significantly lower than in the WT Müller cells. These results indicate that IL-1 increases glutamate uptake in Müller cells by stimulating multiple glutamate transporters including GLAST.

We next examined whether IL-1 alters GLAST expression levels in Müller cells. The RT-PCR analysis amplified the expected 420 bp product using primers specific for GLAST, and IL-1 had no effect on GLAST expression levels (Fig. 1G). The reaction did not result in a product if reverse transcriptase was absent (data not shown). In addition, we evaluated the effects of IL-1 on Müller cell death

by examining extracellular lactate dehydrogenase (LDH) activities. However, IL-1 had no effect on Müller cell viability (103 ± 4% compared with non-treated controls).

Since glutamate transport is coupled with the cotransport of $3Na^+$, the efficiency of glutamate uptake is influenced by both intracellular and extracellular Na^+ concentrations [17]. Accordingly, we next evaluated the effect of GLAST activity and IL-1 on Na^+ concentrations in cultured Müller cells. Müller cells were loaded with the CoroNa Green Na^+ indicator and stimulated with a bath-application of 3 mM glutamate. In the WT Müller cells, the intracellular Na^+ concentration clearly increased in response to glutamate, and IL-1 pretreatment for 24 h significantly suppressed this upregulation (Fig. 2A and B). In contrast, in the GLAST KO Müller cells, neither glutamate stimulation nor IL-1 had a significant effect on the intracellular Na^+ concentration (Fig. 2A and B). These results are consistent with impaired glutamate uptake in GLAST KO Müller cells (Fig. 1F). Elevated intracellular Na^+ concentration is decreased by Na^+/K^+-ATPase, which is dependent on ATP levels [2–4]. Consequently, we further examined whether IL-1 increases ATP synthesis in Müller cells. However, we found that stimulation with IL-1 for 24 h had no effect on ATP synthesis in Müller cells (105 ± 5% compared with non-treated controls). In addition, IL-1 had no effect on the expression levels of Na^+/K^+-ATPase subunits (103 ± 3% in α subunit and 97 ± 4% in β subunit compared with non-treated controls).

Our results suggested that IL-1 may protect retinal neurons from glutamate neurotoxicity by increasing the glutamate uptake through GLAST in Müller cells. In order to confirm this hypothesis, we prepared retinal explants from WT, GLAST KO and EAAC1 KO mice. The WT retinal explants stimulated with 5 mM glutamate for 1 h (Fig. 3B and E) showed a clear decrease in the number of NeuN-positive neurons in the GCL, compared with the non-treated controls (Fig. 3A and D). However, pretreatment of the explants with IL-1 (50 ng/ml) significantly increased the number of surviving RGCs (Fig. 3C, F and S). We carried out similar experiments using the GLAST KO mice. The number of RGCs was significantly decreased in these mice at 3 weeks after birth (Fig. 3G and J), as previously reported [5]. The glutamate stimulation slightly decreased the number of RGCs, but IL-1 failed to protect them (Fig. 3H, I, K, L and S). Finally, we applied glutamate to retinal explants from the EAAC1 KO mice. The number of RGCs was normal in the non-treated controls (Fig. 3M and P) and IL-1 pretreatment significantly prevented glutamate-induced RGC death (Fig. 3N, O, Q, R and S).



Fig. 3. IL-1 protects retinal neurons from glutamate neurotoxicity in WT and EAAC1 KO, but not GLAST KO mice. (A–R) Immunohistochemical analysis of mouse retinal explants from WT (A–F), GLAST KO (G–L) and EAAC1 KO (M–R) mice, stained with an anti-NeuN antibody. Explants were untreated (A, D, G, J, M, P), treated with 5 mM glutamate alone (B, E, H, K, N, Q), or treated with both 50 ng/ml IL-1 and 5 mM glutamate (C, F, I, L, O, R). (S) Quantification of NeuN-positive cells in the GCL. The data are presented as means ± standard errors of three samples for each group. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale bar: 50 μm (A–C, G–I, M–O) and 25 μm (D–F, J–L, P–R).

GLAST is a major, glial-type glutamate transporter expressed in Müller cells [7], and glutamate-induced electrogenic currents are absent in Müller cells that lack GLAST [15]. However, a recent study demonstrated that GLT-1 and EAAC1, as well as GLAST, are expressed in rat retinal glial cells [8]. The authors reported that GLAST expression levels were increased in the context of glutamate and potassium loading, whereas GLT-1 expression increased during hypoxia. These observations suggest that various subtypes of glutamate transporters in Müller cells are involved in retinal physiology and pathology. In the present study, we found that glutamate uptake activity and glutamate-induced intracellular Na^+ accumulation were both severely impaired in Müller cells of GLAST KO mice. We previously proposed a model in which IL-1 increases glutamate uptake in Müller cells by accelerating membrane trafficking rates of Na^+/K^+-ATPase and hence suppressing Na^+ accumulation, which is required for counteracting the Na^+-glutamate cotransport by GLAST [11]. These findings suggest that GLAST plays a key role in the IL-1-mediated glutamate uptake increase in Müller cells.

Glutamate excitotoxicity is associated with various eye diseases, including diabetic retinopathy and glaucoma [5,7,16]. Indeed, we recently reported that our GLAST and EAAC1 KO mice were the first animal models of NTG [5]. Oxidative stress is also involved in glaucoma and other retinal degeneration [1]. Glutathione, a tripeptide of glutamate, cysteine and glycine, plays a key role in protecting RGCs against oxidative stress. Since glutamate uptake is the rate-limiting step in glial glutathione synthesis, activation of glutamate transporters in Müller cells by IL-1 may be an effective strategy for protecting RGCs. In order to explore this possibility, we administered IL-1 to retinal explants from GLAST and EAAC1 KO mice. In the GLAST KO mice, IL-1 failed to protect RGCs from glutamate neurotoxicity. This result is consistent with the severely impaired glutamate uptake in the GLAST KO Müller cells compared with the WT and EAAC1 KO Müller cells. On the other hand, IL-1 partially prevented glutamate neurotoxicity and increased the number of surviving RGCs in the EAAC1 KO mice. Our present results confirm that GLAST is indeed the key transporter that is involved in the IL-1-mediated retinal neuroprotection. However, since IL-1 was still able to increase glutamate uptake in the GLAST KO Müller cells, IL-1 may also stimulate other subtypes of glutamate transporters, such as GLT-1 [8] and currently unidentified glutamate transporters [15].

Our findings suggest that IL-1 may be a viable option for elevating glutamate uptake in the case where GLAST is normally expressed in Müller cells. Accordingly, we have started the genetic analysis of GLAST and EAAC1 in human glaucoma, especially in

NTG patients. To determine whether overexpression of GLAST and IL-1 stimulation may synergistically exert retinal neuroprotective effects, we are currently generating mice that overexpress GLAST. Another important point is that we examined the chronic effect of IL-1 using *ex vivo* culture system. This is because repeated injections of IL-1 to small mouse eyes are difficult and often wound normal retinal tissue. IL-1 is an important mediator of brain injury induced by ischemia or trauma, and has been implicated in chronic brain diseases including Alzheimer's disease, Parkinson's disease, and multiple sclerosis [1,14]. Thus, *in vivo* study to evaluate the long-term effect of IL-1 will be required as the next step to avoid its possible side effects. Further efforts to discover new compounds that can enhance glutamate uptake for a prolonged period may lead to the development of novel strategies for the management of various forms of retinal degeneration, including glaucoma.

Acknowledgements

This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan (K.N., K.T., T.H.), the Ministry of Health, Labour, and Welfare of Japan (Y.M., K.T., T.H.), the Japan Society for the Promotion of Science for Young Scientists (C.H.), the Welfare and Health Funds from Tokyo Metropolitan Government (Y.M.), the Uehara Memorial Foundation, the Naito Foundation, the Suzuken Memorial Foundation, the Daiwa Securities Health Foundation, the Takeda Science Foundation, and the Japan Medical Association (T.H.).

References

[1] S.M. Allan, N.J. Rothwell, Cytokines and acute neurodegeneration, Nat. Rev. Neurosci. 2 (2001) 734–744.
[2] A. Ames 3rd., Y.Y. Li, E.C. Heher, C.R. Kimble, Energy metabolism of rabbit retina as related to function: high cost of Na^+ transport, J. Neurosci. 12 (1992) 840–853.
[3] M. Erecinska, I.A. Silver, Ions and energy in mammalian brain, Prog. Neurobiol. 43 (1994) 37–71.
[4] A.J. Hansen, Ion and membrane changes in the brain during anoxia, Behav. Brain Res. 14 (1984) 93–98.
[5] T. Harada, C. Harada, K. Nakamura, H.M. Quah, A. Okumura, K. Namekata, T. Saeki, M. Aihara, H. Yoshida, A. Mitani, K. Tanaka, The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma, J. Clin. Invest. 117 (2007) 1763–1770.
[6] T. Harada, C. Harada, S. Kohsaka, E. Wada, K. Yoshida, S. Ohno, H. Mamada, K. Tanaka, L.F. Parada, K. Wada, Microglia-Müller glia cell interactions control neurotrophic factor production during light-induced retinal degeneration, J. Neurosci. 22 (2002) 9228–9236.
[7] T. Harada, C. Harada, M. Watanabe, Y. Inoue, T. Sakagawa, N. Nakayama, S. Sasaki, S. Okuyama, K. Watase, K. Wada, K. Tanaka, Functions of the two glutamate transporters GLAST and GLT-1 in the retina, Proc. Natl. Acad. Sci. USA 95 (1998) 4663–4666.
[8] M. Imasawa, K. Kashiwagi, Y. Iizuka, M. Tanaka, S. Tsukahara, Different expression role among glutamate transporters in rat retinal glial cells under various culture conditions, Brain Res. Mol. Brain Res. 142 (2005) 1–8.
[9] A. Iwase, Y. Suzuki, M. Araie, T. Yamamoto, H. Abe, S. Shirato, Y. Kuwayama, H.K. Mishima, H. Shimizu, G. Tomita, Y. Inoue, Y. Kitazawa, Tajimi Study Group, Japan Glaucoma Society, The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study, Ophthalmology 111 (2004) 1641–1648.
[10] J.D. Lindsey, R.N. Weinreb, Elevated intraocular pressure and transgenic applications in the mouse, J. Glaucoma 14 (2005) 318–320.
[11] K. Namekata, C. Harada, K. Kohyama, Y. Matsumoto, T. Harada, Interleukin-1 stimulates glutamate uptake in glial cells by accelerating membrane trafficking of Na^+/K^+-ATPase via actin depolymerization, Mol. Cell. Biol. 28 (2008) 3273–3280.
[12] R. Naskar, C.K. Vorwerk, E.B. Dreyer, Concurrent downregulation of a glutamate transporter and receptor in glaucoma, Invest. Ophthalmol. Vis. Sci. 41 (2000) 1940–1944.
[13] J.D. Rothstein, L. Martin, A.I. Levey, M. Dykes-Hoberg, L. Jin, D. Wu, N. Nash, R.W. Kuncl, Localization of neuronal and glial glutamate transporters, Neuron 13 (1994) 713–725.
[14] N.J. Rothwell, G.N. Luheshi, Interleukin 1 in the brain: biology, pathology and therapeutic target, Trends Neurosci. 23 (2000) 618–625.
[15] V.P. Sarthy, L. Pignataro, T. Pannicke, M. Weick, A. Reichenbach, T. Harada, K. Tanaka, R. Marc, Glutamate transport by retinal Müller cells in glutamate/aspartate transporter-knockout mice, Glia 49 (2005) 184–196.
[16] M. Seki, S.A. Lipton, Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma, Prog. Brain Res. 173 (2008) 495–510.
[17] M. Szatkowski, B. Barbour, D. Attwell, Non-vesicular release of glutamate from glial cells by reversed electrogenic glutamate uptake, Nature 348 (1990) 443–446.
[18] J.L. Wiggs, Genetic etiologies of glaucoma, Arch. Ophthalmol. 125 (2007) 30–37.

Cell Death and Differentiation (2010), 1–9
© 2010 Macmillan Publishers Limited All rights reserved 1350-9047/10 $32.00
www.nature.com/cdd

ASK1 deficiency attenuates neural cell death in GLAST-deficient mice, a model of normal tension glaucoma

C Harada[1], K Namekata[1], X Guo[1], H Yoshida[2], Y Mitamura[3], Y Matsumoto[4], K Tanaka[5], H Ichijo[6] and T Harada*[,1,2]

Apoptosis signal-regulating kinase 1 (ASK1) is an evolutionarily conserved mitogen-activated protein kinase and has an important role in stress-induced retinal ganglion cell (RGC) apoptosis. In the mammalian retina, glutamate/aspartate transporter (GLAST) is a major glutamate transporter, and the loss of GLAST leads to optic nerve degeneration similar to normal tension glaucoma (NTG). In GLAST$^{-/-}$ mice, the glutathione level in the retina is decreased, suggesting the involvement of oxidative stress in NTG pathogenesis. To test this hypothesis, we examined the histology and visual function of GLAST$^{+/-}$:ASK1$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice by multifocal electroretinograms. ASK1 deficiency protected RGCs and decreased the number of degenerating axons in the optic nerve. Consistent with this finding, visual function was significantly improved in GLAST$^{+/-}$:ASK1$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice compared with GLAST$^{+/-}$ and GLAST$^{-/-}$ mice, respectively. The loss of ASK1 had no effects on the production of glutathione or malondialdehyde in the retina or on the intraocular pressure. Tumor necrosis factor (TNF)-induced activation of p38 mitogen-activated protein kinase and the production of inducible nitric oxide synthase were suppressed in ASK1-deficient Müller glial cells. In addition, TNF-induced cell death was suppressed in ASK1-deficient RGCs. These results suggest that ASK1 activation is involved in NTG-like pathology in both neural and glial cells and that interrupting ASK1-dependent pathways could be beneficial in the treatment of glaucoma, including NTG.
Cell Death and Differentiation (2010) **0**, 000–000. doi:10.1038/cdd.2010.62

It is estimated that glaucoma affects nearly 70 million individuals worldwide, including at least 6.8 million who are bilaterally blind.[1] The disease is characterized by the slow progressive degeneration of the retinal ganglion cells (RGCs) and their axons, which are usually associated with elevated intraocular pressure (IOP). Recent studies have shown that glaucoma is affected by multiple genes and environmental factors,[2,3] and there are several inherited and experimentally induced animal models of high IOP glaucoma, including DBA/2J mice and laser-induced chronic ocular hypertension model.[4–6] There is a subtype of glaucoma termed normal tension glaucoma (NTG), however, that presents with statistically normal IOP. The number of NTG patients has been thought to be small relative to the total number of glaucoma patients, but recent studies have revealed an unexpectedly high prevalence of NTG.[7] These findings suggest that non-IOP-dependent factors may contribute to disease progression, and elucidating these factors is necessary to better understand the pathogenesis of glaucoma, especially in the context of NTG. For this purpose, an animal model representing disease characteristics of NTG would be extremely useful. To date, some animal models have been introduced, for example, the optic nerve ligation model shows RGC loss with normal IOP,[8] but this is more suitable as a model of ischemia or optic nerve injury. In addition, preparation of these artificial models requires a high level of technical skills, but unfortunately, long-term reproducibility seems to be somewhat limited. Thus, there has been a great demand to create suitable animal models of NTG.

In addition to more extensively studied factors such as reduced ocular blood flow and systemic blood pressure changes, excessive stimulation of the glutamatergic system has been proposed to contribute to the death of RGCs in glaucoma. Excessive extracellular concentrations

Q1
Q2
Q3

[1]Department of Molecular Neurobiology, Tokyo Metropolitan Institute for Neuroscience, Tokyo Metropolitan Organization for Medical Research, Tokyo, Japan; [2]Department of Neuro-ophthalmology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan; [3]Department of Ophthalmology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan; [4]Department of Molecular Neuropathology, Tokyo Metropolitan Institute for Neuroscience, Tokyo Metropolitan Organization for Medical Research, Tokyo, Japan; [5]Laboratory of Molecular Neuroscience, School of Biomedical Science and Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan and [6]Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, Strategic Approach to Drug Discovery and Development in Pharmaceutical Sciences, Global Center of Excellence program, and Core Research for Evolutional Science and Technology, Japan; Science and Technology Corporation, The University of Tokyo, Tokyo, Japan
*Correspondence: T Harada, Department of Molecular Neurobiology, Tokyo Metropolitan Institute for Neuroscience, Tokyo Metropolitan Organization for Medical Research, 2-6 Musashidai, Fuchu, Tokyo 183-8526, Japan. Tel: +81 42 325 3881; Fax: +81 42 321 8678; E-mail: harada-tk@igakuken.or.jp
Keywords: glaucoma; ASK1; glutamate transporter; glia; neural cell death
Abbreviations: ASK1, apoptosis signal-regulating kinase 1; GLAST, glutamate/aspartate transporter; NTG, normal tension glaucoma; Aβ, amyloid beta; GDNF, glial cell line-derived neurotrophic factor; GLT-1, glutamate transporter 1; iNOS, inducible nitric oxide synthase; IL-1, interleukin-1; IOP, intraocular pressure; MAPK, mitogen-activated protein kinase; mfERGs, multifocal electroretinograms; NO, nitric oxide; NTN, neurturin; RGC, retinal ganglion cell; ROS, reactive oxygen species; TLR4, Toll-like receptor 4; TNF, tumor necrosis factor
Received 28.12.09; revised 22.3.10; accepted 15.4.10; Edited by N Bazan

Journal: CDD ☐ Disk used Despatch Date: 7/5/2010
Article : npg_cdd_cdd201062 Pages: 1–10 OP: XXX ED: XXX CE: XXX Graphic: 1-4 col

of glutamate induce uncontrolled elevation of intracellular calcium, which enters through chronically activated glutamate receptors. Glutamate uptake by the glial cells is a well-known mechanism to maintain low extracellular levels of glutamate and promote efficient interneuronal signaling in the central nervous system (CNS). Furthermore, the same process is considered to be neuroprotective during neurodegeneration. Clearance of glutamate from the extracellular space is accomplished primarily by the action of glutamate transporters.[9] In the CNS, the glutamate/aspartate transporter (GLAST) and glutamate transporter 1 (GLT-1) are Na^+-dependent glutamate transporters found in astrocytes. Genetic deletion of GLAST and/or GLT-1 causes abnormal brain development and neurological symptoms such as motor deficits.[9–11] We have previously reported that GLAST, located in Müller glial cells, is the only glial-type glutamate transporter in the retina, whereas GLT-1 is expressed in neurons, including bipolar cells and photoreceptors.[12] Not surprisingly, GLAST is more active than GLT-1 in preventing glutamate neurotoxicity after ischemia.[12] In addition, we recently found that GLAST-deficient ($GLAST^{-/-}$ and $GLAST^{+/-}$) mice show spontaneous RGC death and optic nerve degeneration without elevated IOP.[13] Interestingly, GLAST is essential not only to keep the extracellular glutamate concentration below a neurotoxic level but also to maintain glutathione levels by transporting glutamate, which is a substrate for glutathione synthesis, into Müller cells. As retinal concentration of glutathione, a major cellular antioxidant in the retina, was decreased in GLAST-deficient mice, both glutamate neurotoxicity and oxidative stress may be involved in NTG-like pathology.[13] Together with the evidence that downregulation of GLAST (human EAAT1) in the retina and of glutathione level in the plasma are found in human glaucoma patients,[14,15] it is appropriate to consider GLAST-deficient mice as a valid and adequate model that offer a powerful system to determine the mechanisms of and evaluate new treatments for NTG.

Apoptosis signal-regulating kinase 1 (ASK1) has key roles in human diseases closely related to the dysfunction of cellular responses to oxidative stress and endoplasmic reticulum stressors, including neurodegenerative diseases.[16,17] We have previously reported that ASK1 is primarily expressed in RGCs, and $ASK1^{-/-}$ mice are less susceptible to ischemic injury.[18] The role of ASK1 in glaucoma, however, is unknown. In an attempt to identify the apoptotic signals regulating RGC death in GLAST-deficient mice, we generated



Figure 1 Effect of ASK1 on visual response in $GLAST^{+/-}$ and $GLAST^{-/-}$ mice. (**a**) Summed responses of the second-order kernel examined using multifocal electroretinograms. (**b**) Averaged responses of the second-order kernel are demonstrated using three-dimensional plots. The degree of retinal function is presented in the color bar. A higher score (red) indicates highly sensitive visual function and a lower score (green) indicates retinal dysfunction. (**c**) Quantitative analysis of the visual response amplitude. Note the improved visual function of $GLAST^{+/-}$:$ASK1^{-/-}$ and $GLAST^{-/-}$:$ASK1^{-/-}$ mice compared with $GLAST^{+/-}$ and $GLAST^{-/-}$ mice, respectively. Values are given in nV per square degree (nV/deg^2). $^{**}P<0.01$, $^{*}P<0.05$

NPG.CDD.CDD201062

GLAST$^{+/-}$:ASK1$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice and determined the effect of ASK1 deficiency on the NTG-like phenotype.

Results

ASK1 deficiency protects visual function in GLAST-deficient mice. To determine whether ASK1 deficiency is capable of preventing the NTG-like phenotype in GLAST-deficient mice,[13] GLAST$^{+/-}$:ASK1$^{+/-}$ mice were interbred and genotyped at weaning. GLAST$^{+/-}$:ASK1$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice were born in accordance with Mendelian inheritance ratios, survived into adulthood and were fertile. We first examined the visual function of these mice at 3 months of age (3 M) using multifocal electroretinograms (mfERGs), an established noninvasive method.[13] Figure 1a and b show the averaged responses of the second-order kernel in each group. The visual function of WT and ASK1$^{-/-}$ mice was indistinguishable (Figure 1c). As we have previously reported, visual function in the GLAST$^{+/-}$ and GLAST$^{-/-}$ mice was impaired in all visual fields, but was clearly improved by ASK1 deficiency (Figure 1a–c). In particular, the amplitude of the secondary kernel in GLAST$^{+/-}$:ASK1$^{-/-}$ mice (4.7 ± 0.4 nV/deg^2; $n=8$) was not significantly different compared with WT mice (5.0 ± 0.3 nV/deg^2; $n=9$) ($P=0.67$, Figure 1c). These results suggest that ASK1 deficiency has no harmful effects during development and prevents visual disturbances in GLAST-deficient mice.

Q4

ASK1 deficiency protects retinal neurons in GLAST-deficient mice. We next analyzed the histopathology of the retina. Consistent with the results of the mfERGs, the retina of ASK1$^{-/-}$ mice showed normal organization at 3 weeks (3 W), 3 M and 6 M (Figure 2). Cell number in the ganglion cell layer (GCL) was significantly decreased after 3 M in GLAST$^{+/-}$ mice and after 3 W in GLAST$^{-/-}$ mice (Figures 2 and 3a). In addition, the thickness of the inner retinal layer (IRL) was decreased after 3 M in both strains (Figure 3b). In GLAST$^{+/-}$:ASK1$^{-/-}$ mice, however, GCL cell number was significantly increased at 3 M and 6 M compared with GLAST$^{+/-}$ mice (Figure 3a). IRL thickness was increased to a normal level ($105 \pm 11\%$ at 3 M and $95 \pm 11\%$ at 6 M; $n=6$) in GLAST$^{+/-}$:ASK1$^{-/-}$ mice (Figure 3b). In GLAST$^{-/-}$:ASK1$^{-/-}$ mice, IRL thickness was significantly increased at 3 M and 6 M compared with GLAST$^{-/-}$ mice (Figure 3b). In addition, GCL cell number was increased at 3 W and 3 M, but not at 6 M (Figure 3a). These results suggest that ASK1 deficiency prevents the loss of RGCs and secondary retinal degeneration in GLAST-deficient mice.

ASK1 deficiency prevents optic nerve degeneration in GLAST-deficient mice. As nearly half of the cells in the rodent GCL are displaced amacrine cells, we needed to distinguish RGCs from displaced amacrine cells by retrograde labeling.[18] As ASK1 deficiency was most effective in 3 M GLAST$^{+/-}$ mice, we examined RGC number in WT, ASK1$^{-/-}$, GLAST$^{+/-}$ and GLAST$^{+/-}$:ASK1$^{-/-}$ mice at 3 M (Figure 4a–h). RGC number per square millimeter in ASK1$^{-/-}$ mice (4200 ± 238; $n=3$) was normal compared with WT mice (4050 ± 170; $n=3$) ($P=0.64$, Figure 4m. In GLAST$^{+/-}$ mice, RGC number (3358 ± 180; $n=3$) was significantly reduced compared with WT mice ($P<0.05$). However, RGC number in GLAST$^{+/-}$:ASK1$^{-/-}$ mice (4067 ± 121; $n=3$) was clearly increased compared with



Figure 2 Effect of ASK1 on the progress of glaucoma. H&E staining of retinal sections at 3 weeks, 3 months and 8 months. WT, GLAST$^{+/-}$ and GLAST$^{-/-}$ mice were littermates. GLAST$^{+/-}$:ASK1$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice were littermates. Scale bar: 100 and 400 μm in the upper and lower rows, respectively. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer

NPG.CDD.CDD201062



Figure 3 Quantification of the severity of glaucoma. (**a**) RGC number in WT, ASK1$^{-/-}$, GLAST$^{+/-}$, GLAST$^{+/-}$:ASK1$^{-/-}$, GLAST$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice. The number of neurons in the GCL was counted in retinal sections from one ora serrata through the optic nerve to the other ora serrata. (**b**) Thickness of the inner retinal layer in WT, ASK1$^{-/-}$, GLAST$^{+/-}$, GLAST$^{+/-}$:ASK1$^{-/-}$, GLAST$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice. $^{**}P<0.01$, $^{*}P<0.05$

GLAST$^{+/-}$ mice ($P<0.05$) and in normal range compared with WT mice ($P=0.94$, Figure 4m). Similarly, RGC number in GLAST$^{-/-}$:ASK1$^{-/-}$ mice (3392 ± 102; $n=3$) was increased compared with GLAST$^{-/-}$ mice (2592 ± 269; $n=3$) ($P<0.05$,Figure 4m).

Degeneration of the optic nerve is one of the hallmarks of glaucoma. To analyze morphological changes in the optic nerve, semi-thin transverse sections were cut and stained with toluidine blue (Figure 4i–l). Consistent with severe RGC loss, the degenerating axons in 3 M GLAST$^{+/-}$ mice had abnormally dark axonal profiles (arrowheads in Figure 4k). Such degenerating axons, however, were almost absent in GLAST$^{+/-}$:ASK1$^{-/-}$ mice (Figure 4l). Taken together, these results demonstrate that ASK1 deficiency protects against RGC loss and optic nerve degeneration in GLAST-deficient mice, which leads to improved visual function as detected by mfERG (Figure 1).

IOP measurement in GLAST/ASK1 double-deficient mice. We have previously reported that GLAST-deficient mice show normal IOP compared with WT mice.[13] To determine the effect of ASK1 on IOP, we examined the IOP of ASK1$^{-/-}$, GLAST$^{+/-}$:ASK1$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice. IOP measurements were carried out at around 2100 hours, when IOP is highest in mouse eyes.[19] The IOP values of ASK1$^{-/-}$, GLAST$^{+/-}$:ASK1$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice were not significantly decreased compared with WT and GLAST$^{-/-}$ mice (Figure 5). These results suggest that the recovery of NTG-like pathology in GLAST$^{+/-}$:ASK1$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice is IOP independent.

Role of oxidative stress and glutamate neurotoxicity in GLAST/ASK1 double-deficient mice. Oxidative stress has been proposed to contribute to RGC death in glaucoma, and a reduction in glutathione levels was reported in the plasma of human glaucoma patients.[15] Consistent with these findings, we have previously reported a decreased glutathione concentration in the retina of GLAST$^{-/-}$ mice.[13] To determine the effect of ASK1 on glutathione synthesis, we examined the glutathione concentration in the retina of 6 M ASK1$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice and found that it was not significantly increased compared with WT and GLAST$^{-/-}$ mice, respectively (Figure 6a). In addition, the malondialdehyde concentration in the retina of ASK1$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice was indistinguishable from that of WT and GLAST$^{-/-}$ mice, respectively (Figure 6b).

We have previously reported that intravitreal glutamate concentration is normal, but memantine, *N*-methyl-D-aspartate receptor antagonist, partially protected RGCs in GLAST$^{-/-}$ mice.[13] In addition, we showed that GLAST has a major role in glutamate uptake into Müller glial cells.[20] To explore the possibility that ASK1 is involved in glutamate transport, we examined glutamate uptake activity in Müller glial cells prepared from ASK1$^{-/-}$ and GLAST$^{+/-}$:ASK1$^{-/-}$ mice, and found that it was not significantly increased compared with WT and GLAST$^{+/-}$ mice, respectively (Figure 7). These findings suggest that ASK1 deficiency attenuates NTG-like degeneration without affecting the conditions of oxidative stress and glutamate neurotoxicity in GLAST-deficient mice.

Effect of ASK1-p38 mitogen-activated protein kinase (MAPK) signaling in Müller glial cells and RGCs. ASK1 is activated in response to cytotoxic stresses, including reactive oxygen species (ROS) and tumor necrosis factor (TNF), and relays these signals to p38 MAPK.[16,17] To determine whether this pathway is active in Müller glial cells, we first examined the effects of TNF on cultured Müller cells from WT and ASK1$^{-/-}$ mice. Western blot analysis demonstrated that stimulation of WT Müller cells with TNF leads to strong phosphorylation of p38 in a dose-dependent manner (Figure 8a). The activation of p38, however, was significantly suppressed in ASK1-deficient Müller cells (Figure 8a). Nitric oxide (NO) generated by inducible nitric oxide synthase (iNOS) is involved in retinal neuronal cell death,[21,22] and a previous study has reported that TNF-induced iNOS expression and NO release are suppressed by a specific inhibitor of p38 in mouse astrocytes.[23] These results suggest that the ASK1-p38 pathway regulates TNF-induced iNOS expression in Müller cells. To evaluate this possibility, we next examined iNOS

NPG.CDD.CDD201062



Figure 4 Effect of ASK1 on RGC and optic nerve degeneration. (**a–h**) Retrogradely labeled RGCs in WT, ASK1$^{-/-}$, GLAST$^{+/-}$ and GLAST$^{+/-}$:ASK1$^{-/-}$ mice. (**e–h**) Magnified images of (**a–d**), respectively. (**i–l**) Staining of semi-thin sections with toluidine blue revealed the presence of abnormally dark axonal profiles (arrowheads) and reduced axons in GLAST$^{+/-}$ mice (**k**), which was ameliorated in GLAST$^{+/-}$:ASK1$^{-/-}$ mice (**l**). (**m**) Quantification of labeled RGC number in WT, ASK1$^{-/-}$, GLAST$^{+/-}$, GLAST$^{+/-}$:ASK1$^{-/-}$, GLAST$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice. Scale bar: 1 mm (**a–d**); 200 μm (**e–h**); 20 μm (**i–l**). $^*P<0.05$

protein levels in cultured Müller cells. In untreated Müller cells, iNOS protein was almost absent, but TNF clearly increased iNOS expression levels (Figure 8b). Similar iNOS induction was detected in GLAST-deficient Müller cells (Figure 8b). However, TNF-induced iNOS expression was completely suppressed in ASK1-deficient Müller cells (Figure 8b). These results suggest that the ASK1-p38 pathway is required in Müller cells for the TNF-induced iNOS production, which may lead to the death of retinal neurons including RGCs. We further examined the direct effect of TNF on cultured RGCs.[18] TNF-induced cell death in cultured RGCs from ASK1-deficient mice was significantly decreased (41 ± 9%; $n=6$) compared with that from WT mice ($P<0.05$, Figure 8c). Taken together, loss of ASK1 prevents TNF-induced RGC death through both the direct pathway and the indirect pathway through Müller cells that is independent of GLAST.

Discussion

In this study, we show that ASK1 is associated with progressive RGC loss, glaucomatous optic nerve degeneration and visual disturbances in GLAST-deficient mice. We previously suggested the possibility that dysfunction of

NPG.CDD.CDD201062



Figure 5 Effect of ASK1 on intraocular pressure in GLAST$^{+/-}$ and GLAST$^{-/-}$ mice. Intraocular pressure in GLAST$^{+/-}$:ASK1$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice was not significantly decreased compared with GLAST$^{-/-}$ mice



Figure 6 Effect of ASK1 on oxidative stress in GLAST$^{-/-}$ mice. (**a**) Mean glutathione concentration in whole retinas from WT, ASK1$^{-/-}$, GLAST$^{+/-}$, GLAST$^{+/-}$:ASK1$^{-/-}$, GLAST$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice. (**b**) Malondialdehyde concentration in whole retinas from WT, ASK1$^{-/-}$, GLAST$^{+/-}$, GLAST$^{+/-}$:ASK1$^{-/-}$, GLAST$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice. $^{*}P<0.05$

GLAST (human EAAT1) has a role in RGC death in human NTG.[13] It has been reported that EAAT1 is downregulated in the retinas of human patients with glaucoma[14] and in fibroblasts from patients with Alzheimer's disease.[24] Considering the high frequency of glaucoma in Alzheimer's disease patients,[25] common mechanisms such as GLAST dysfunction might contribute to both diseases. Interestingly, ROS-mediated ASK1 activation is a key mechanism for amyloid beta (Aβ)-induced neurotoxicity, which has a central role in Alzheimer's disease.[26] The accumulation of Aβ is also observed in apoptotic RGCs in a rat model of glaucoma due to high IOP.[27] In this model, inhibiting amyloidogenic pathways by agents affecting multiple stages of the Aβ pathway reduces RGC apoptosis *in vivo*.[27] This suggests a new hypothesis for RGC death in glaucoma involving ASK1-dependent Aβ neurotoxicity, mimicking Alzheimer's disease.[28] In addition, multiple single-nucleotide polymorphisms in the Toll-like receptor 4 (*TLR4*) gene have been associated with the risk of NTG.[29] As ASK1 is required for innate immune responses dependent on TLR4,[30] TLR4-ASK1 signaling may be involved in the development of NTG. Taken together, these findings suggest that ASK1 may have roles in various neurodegenerative disorders, including glaucoma.[16–18]

Q5

Our present results demonstrate reduced RGC death, decreased axonal loss and mild visual disturbance in GLAST$^{+/-}$:ASK1$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice, highlighting ASK1 as a potential therapeutic target for NTG. Loss of ASK1 had no effect on IOP (Figure 5), the production of malondialdehyde (Figure 6) or glutamate uptake activity by Müller cells (Figure 7). Whereas TNF-induced iNOS production was suppressed in ASK1-deficient Müller cells, and ASK1-deficient RGCs were more resistant to TNF-induced death compared with WT RGCs (Figure 8). Thus, in combination with conventional treatments to lower IOP, inhibition of ASK1 signaling may be useful in the treatment of glaucoma. In addition, we recently reported that interleukin-1 (IL-1) increases glutamate uptake by Müller cells, primarily through the activation of GLAST, and protects RGCs from glutamate neurotoxicity.[20,31] IL-1 is a mediator of brain injury induced by ischemia or trauma and has been implicated in chronic brain diseases, such as Alzheimer's disease, Parkinson's disease and multiple sclerosis.[32] Therefore, we need to examine the beneficial and detrimental roles of IL-1 during glaucoma *in vivo*. Furthermore, we are undertaking experiments to determine the neuroprotective effect of GLAST against neurotoxicity, axotomy and neuroinflammation in mice overexpressing GLAST.

A recent study has shown that upregulation of GLAST in Müller cells by glial cell line-derived neurotrophic factor (GDNF) and neurturin (NTN) is required to rescue RGCs following optic nerve transection.[33] As the receptors for GDNF and NTN are increased in Müller cells after RGC axotomy, the neuroprotective effects of GDNF and NTN may be indirect, at

NPG.CDD.CDD201062



Figure 7 Glutamate uptake activity in Müller cells derived from WT, ASK1$^{-/-}$, GLAST$^{+/-}$ and GLAST$^{+/-}$:ASK1$^{-/-}$ mice. The data are presented as means ± S.E.M. of eight samples for each group. *$P<0.05$



Figure 8 ASK1 is required for TNF-induced p38 activation and iNOS production in Müller glial cells. (**a**) Effect of ASK1 on TNF-induced p38 activation. Müller cells derived from WT or ASK1$^{-/-}$ mice were stimulated with the indicated concentration of TNF for 20 min, followed by immunoblot analysis of total and phosphorylated p38 in cell lysates. (**b**) Effect of GLAST and ASK1 on TNF-induced iNOS production. Müller cells derived from WT, GLAST$^{-/-}$ or ASK1$^{-/-}$ mice were stimulated for 16 h with TNF (50 ng/ml) or left unstimulated. (**c**) Effect of TNF on RGC death. RGCs derived from WT or ASK1$^{-/-}$ mice were treated for 2 days with TNF (400 ng/ml), and the number of PI-positive cells was counted. The data are presented as mean ± S.E.M. of six samples for each group

least partly, through the enhancement of glutamate uptake in Müller cells. Similar upregulation of the receptors for GDNF and NTN has been observed in a rat model of photoreceptor degeneration.[34,35] In this animal model, trophic factors such as nerve growth factor, brain-derived neurotrophic factor and basic fibroblast growth factor increase the production of multiple trophic factors in Müller cells, which indirectly leads to photoreceptor survival.[35–37] In addition, nerve growth factor eye drops may prevent the progress of human glaucoma.[38] In this study, we found that the loss of ASK1 prevented the activity of p38 and TNF-induced iNOS production in Müller cells (Figure 8). Recent studies have shown that TNF and NO can induce RGC death and involved in the pathophysiology of glaucoma.[39–41] Our results suggest that the ASK1-p38 pathway is involved in the process of TNF-induced RGC degeneration in neighboring glial cells, as well as in the RGC itself (Figure 8).[18] Taken together, these findings suggest that such a glial–neuronal network may be functional in various forms of neurodegenerative diseases and that ASK1, NO, GLAST and trophic factors in Müller cells have important roles in this network during glaucoma.[42,43] Thus, further efforts to discover new compounds that can enhance glutamate uptake and inhibit ASK1 signaling for a prolonged period may lead to the development of novel strategies for the management of glaucoma, including NTG.

Materials and Methods

Mice. Experiments were carried out using ASK1$^{-/-}$,[18] GLAST$^{+/-}$ and GLAST$^{-/-}$ mice[12,13] in accordance with the Tokyo Metropolitan Institute for Neuroscience *Guidelines for the Care and Use of Animals*. After mating ASK1$^{-/-}$ and GLAST$^{-/-}$ mice, GLAST$^{+/-}$:ASK1$^{+/-}$ mice were interbred to obtain GLAST$^{+/-}$:ASK1$^{-/-}$ and GLAST$^{-/-}$:ASK1$^{-/-}$ mice.

Histological and morphometric studies. Paraffin retinal sections of 7 μm thickness were cut through the optic nerve and stained with hematoxylin and eosin. RGC number and the extent of retinal degeneration were quantified in three ways.[18] First, the thickness of the IRL (between the internal limiting membrane and the interface of the outer plexiform layer and the outer nuclear layer) was analyzed. Second, in the same sections, the number of neurons in GCL was counted from one ora serrata through the optic nerve to the other ora serrata. Third, RGCs were retrogradely labeled from the superior colliculus with Fluoro-Gold (FG; Fluorochrome, Englewood, CO, USA). At 7 days after FG application, the eyes were enucleated, and the retinas were detached and prepared as flattened whole mounts in 4% PFA in 0.1 M PBS solution. The GCL was examined in whole-mounted retinas with fluorescence microscopy to determine RGC density. Four standard areas (0.04 mm^2) of each retina at a point 0.1 mm from the optic disc were randomly chosen. Labeled cells were counted by observers blinded to the identity of the mice, and the average number of RGCs/mm^2 was calculated. The changes in RGC number were expressed as a percentage of the WT control eyes.

For detailed morphological analysis, optic nerves were fixed in 2% glutaraldehyde and 2% paraformaldehyde in 0.1 M phosphate buffer overnight at 4°C. After dissection, the pieces of tissue were placed in 1% osmium tetroxide, and after dehydration, the pieces were embedded in Epon. Transverse semi-thin (1 μm) sections were stained with 0.2% toluidine blue in 1.0% sodium borate.[13,44]

Q6

IOP measurement. IOP was measured by a previously validated commercial rebound tonometer (TonoLab; Colonial Medical Supply, Franconia, NH, USA) in anesthetized mice as reported previously.[45] To minimize variation, the data were collected during a time window 4–6 min after injection of the anesthetic during which IOP plateaus. The animals were 6 months of age, and their body weights ranged from 22–36 g at the time of IOP measurement. As the 24-h IOP pattern in mouse eyes is biphasic, with IOP being highest around 2100 hours,[19] we examined IOP between 2000 and 2300 hours.

NPG.CDD.CDD201062

mfERG. Mice (3 months old) were anesthetized by intraperitoneal injection of a mixture of xylazine (10 mg/kg) and ketamine (25 mg/kg). The pupils were dilated with 0.5% phenylephrine hydrochloride and 0.5% tropicamide. mfERGs were recorded using a VERIS 6.0 system (Electro-Diagnostic Imaging, Redwood City, CA, USA). The visual stimulus consisted of seven hexagonal areas scaled with eccentricity. The stimulus array was displayed on a high-resolution black and white monitor driven at a frame rate of 100 Hz. The second-order kernel, which is impaired in patients with glaucoma, was analyzed.[13,44]

Malondialdehyde and glutathione assay. The concentrations of malondialdehyde and glutathione were measured using the Bioxytech LPO-586 (Oxis Research, Beverly Hills, CA, USA) and Glutathione Assay Kit (Cayman Chemical, Ann Arbor, MI, USA), according to the manufacturers' protocols.

Glutamate uptake assay. Glutamate uptake assay in primary cultured Müller cells was carried out as previously reported.[20,31] Müller cells were cultured in 5.5 mM glucose-containing DMEM supplemented with 10% fetal bovine serum. The culture media were replaced with a modified Hanks' balanced salt solution (HBSS) for a 20-min preincubation, before the addition of 0.025 mCi/ml L-[^{3}H]-glutamate (Amersham, Uppsala, Sweden) and 100 μM unlabeled glutamate to the media. Uptake was terminated after 7 min by three washes in ice-cold HBSS, immediately followed by cell lysis in 0.1 M NaOH. Aliquots were taken for scintillation counting, and protein concentration was determined using BSA standards.

Immunoblot analysis. Primary Müller cells were obtained as previously reported[35–37] and treated with TNF at various concentrations for 20 min or 16 h. Immunoblotting was carried out as previously reported.[20,31] Membranes were incubated with antibodies against p38 (1 : 1000; BD Biosciences Pharmingen, San Diego, CA, USA), phospho-p38 (1 : 1000; BD Biosciences Pharmingen) or iNOS (1 : 1000; BD Biosciences Pharmingen).

Assessment of TNF-induced cell death in cultured RGCs. RGCs derived form WT and ASK1$^{-/-}$ mice were seeded at a density of 5×10^4 cells per well and cultured with 0.1 ml of medium on a 96-well culture plate.[18] After 2 days, they were stimulated with 400 ng/ml of TNF for 2 days, and dying RGC number was counted after staining with propidium iodide.

Statistics. For statistical comparison of two samples, we used a two-tailed Student's *t*-test. Data are presented as the mean ± S.E.M. $P < 0.05$ was regarded as statistically significant.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgements. We thank Atsuko Kimura and Rikako Shimizu for technical assistance. This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan (KN, KT, HI, TH); the Ministry of Health, Labour and Welfare of Japan (YM, KT, TH); the Japan Society for the Promotion of Science for Young Scientists (CH); the Welfare and Health Funds from the Tokyo Metropolitan Government (YM); the Uehara Memorial Foundation; the Naito Foundation; the Suzuken Memorial Foundation; the Daiwa Securities Health Foundation; the Takeda Science Foundation and the Japan Medical Association (TH).

1. Quigley HA. Number of people with glaucoma worldwide. *Br J Ophthalmol* 1996; **80**: 389–393.
2. Wiggs JL. Genetic etiologies of glaucoma. *Arch Ophthalmol* 2007; **125**: 30–37.
3. Seki M, Lipton SA. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma. *Prog Brain Res* 2008; **173**: 495–510.
4. Lindsey JD, Weinreb RN. Elevated intraocular pressure and transgenic applications in the mouse. *J Glaucoma* 2005; **14**: 318–320.
5. John SW, Smith RS, Savinova OV, Hawes N, Chang B, Turnbull D *et al.* Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. *Invest Ophthalmol Vis Sci* 1998; **39**: 951–962.
6. Chiu K, Chang R, So KF. Laser-induced chronic ocular hypertension model on SD rats. *J Vis Exp* 2007; **10**: 549.
7. Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S *et al.* The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. *Ophthalmology* 2004; **111**: 1641–1648.
8. Zhang X, Cheng M, Chintala SK. Optic nerve ligation leads to astrocyte-associated matrix metalloproteinase-9 induction in the mouse retina. *Neurosci Lett* 2004; **356**: 140–144.
9. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K *et al.* Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. *Science* 1997; **276**: 1699–1702.
10. Watase K, Hashimoto K, Kano M, Yamada K, Watanabe M, Inoue Y *et al.* Motor discoordination and increased susceptibility to cerebellar injury in GLAST mutant mice. *Eur J Neurosci* 1998; **10**: 976–988.
11. Matsugami TR, Tanemura K, Mieda M, Nakatomi R, Yamada K, Kondo T *et al.* Indispensability of the glutamate transporters GLAST and GLT1 to brain development. *Proc Natl Acad Sci USA* 2006; **103**: 12161–12166.
12. Harada T, Harada C, Watanabe M, Inoue Y, Sakagawa T, Nakayama N *et al.* Functions of the two glutamate transporters GLAST and GLT-1 in the retina. *Proc Natl Acad Sci USA* 1998; **95**: 4663–4666.
13. Harada T, Harada C, Nakamura K, Quah HA, Okumura A, Namekata K *et al.* The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma. *J Clin Invest* 2007; **117**: 1763–1770.
14. Naskar R, Vorwerk CK, Dreyer EB. Concurrent downregulation of a glutamate transporter and receptor in glaucoma. *Invest Ophthalmol Vis Sci* 2000; **41**: 1940–1944.
15. Gherghel D, Griffiths HR, Hilton EJ, Cunliffe IA, Hosking SL. Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. *Invest Ophthalmol Vis Sci* 2005; **46**: 877–883.
16. Nishitoh H, Kadowaki H, Nagai A, Maruyama T, Yokota T, Fukutomi H *et al.* ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. *Genes Dev* 2008; **22**: 1451–1464.
17. Hattori K, Naguro I, Runchel C, Ichijo H. The roles of ASK family proteins in stress responses and diseases. *Cell Commun Signal* 2009; **24**: 7–9.
18. Harada C, Nakamura K, Namekata K, Okumura A, Mitamura Y, Iizuka Y *et al.* Role of apoptosis signal-regulating kinase 1 in stress-induced neural cell apoptosis *in vivo*. *Am J Pathol* 2006; **168**: 261–269.
19. Aihara M, Lindsey JD, Weinreb RN. Twenty-four-hour pattern of mouse intraocular pressure. *Exp Eye Res* 2003; **77**: 681–686.
20. Namekata K, Harada C, Guo X, Kikushima K, Kimura A, Fuse N *et al.* Interleukin-1 attenuates normal tension glaucoma-like retinal degeneration in EAAC1 deficient mice. *Neurosci Lett* 2009; **465**: 160–164.
21. Hangai M, Yoshimura N, Hiroi K, Mandai M, Honda Y. Inducible nitric oxide synthase in retinal ischemia-reperfusion injury. *Exp Eye Res* 1996; **63**: 501–509.
22. Goureau O, Régnier-Ricard F, Courtois Y. Requirement for nitric oxide in retinal neuronal cell death induced by activated Müller glial cells. *J Neurochem* 1999; **72**: 2506–2515.
23. Da Silva J, Pierrat B, Mary JL, Lesslauer W. Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes. *J Biol Chem* 1997; **272**: 28373–28380.
24. Zoia CP, Tagliabue E, Isella V, Begni B, Fumagalli L, Brighina L *et al.* Fibroblast glutamate transport in aging and in AD: correlations with disease severity. *Neurobiol Aging* 2005; **26**: 825–832.
25. Tamura H, Kawakami H, Kanamoto T, Kato T, Yokoyama T, Sasaki K *et al.* High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. *J Neurol Sci* 2006; **246**: 79–83.
26. Kadowaki H, Nishitoh H, Urano F, Sadamitsu C, Matsuzawa A, Takeda K *et al.* Amyloid beta induces neuronal cell death through ROS-mediated ASK1 activation. *Cell Death Differ* 2005; **12**: 19–24.
27. Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A *et al.* Targeting amyloid-beta in glaucoma treatment. *Proc Natl Acad Sci USA* 2007; **104**: 13444–13449.
28. McKinnon SJ. Glaucoma: ocular Alzheimer's disease? *Front Biosci* 2003; **8**: 1140–1156.
29. Shibuya E, Meguro A, Ota M, Kashiwagi K, Mabuchi F, Iijima H *et al.* Association of Toll-like receptor 4 gene polymorphisms with normal tension glaucoma. *Invest Ophthalmol Vis Sci* 2008; **49**: 4453–4457.
30. Matsuzawa A, Saegusa K, Noguchi T, Sadamitsu C, Nishitoh H, Nagai S *et al.* ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. *Nat Immunol* 2005; **6**: 587–592.
31. Namekata K, Harada C, Kohyama K, Matsumoto Y, Harada T. Interleukin-1 stimulates glutamate uptake in glial cells by accelerating membrane trafficking of Na$^+$/K$^+$-ATPase via actin depolymerization. *Mol Cell Biol* 2008; **28**: 3273–3280.
32. Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. *Trends Neurosci* 2000; **23**: 618–625.
33. Koeberle PD, Bähr M. The upregulation of GLAST-1 is an indirect antiapoptotic mechanism of GDNF and neurturin in the adult CNS. *Cell Death Differ* 2008; **15**: 471–483.
34. Jomary C, Thomas M, Grist J, Milbrandt J, Neal MJ, Jones SE. Expression patterns of neurturin and its receptor components in developing and degenerative mouse retina. *Invest Ophthalmol Vis Sci* 1999; **40**: 568–574.
35. Harada C, Harada T, Quah HM, Maekawa F, Yoshida K, Ohno S *et al.* Potential role of glial cell line-derived neurotrophic factor receptors in Müller glial cells during light-induced retinal degeneration. *Neuroscience* 2003; **122**: 229–235.

NPG.CDD.CDD201062

36. Harada T, Harada C, Kohsaka S, Wada E, Yoshida K, Ohno S *et al.* Microglia-Müller glia cell interactions control neurotrophic factor production during light-induced retinal degeneration. *J Neurosci* 2002; **22**: 9228–9236.
37. Harada T, Harada C, Nakayama N, Okuyama S, Yoshida K, Kohsaka S *et al.* Modification of glial-neuronal cell interactions prevents photoreceptor apoptosis during light-induced retinal degeneration. *Neuron* 2000; **26**: 533–541.
38. Lambiase A, Aloe L, Centofanti M, Parisi V, Mantelli F, Colafrancesco V *et al.* Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. *Proc Natl Acad Sci USA* 2009; **106**: 13469–13474.
39. Osborne NN. Pathogenesis of ganglion 'cell death' in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria. *Prog Brain Res* 2008; **173**: 339–352.
40. Nakazawa T, Nakazawa C, Matsubara A, Noda K, Hisatomi T, She H *et al.* Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. *J Neurosci* 2006; **26**: 12633–12641.
41. Toda N, Nakanishi-Toda M. Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy. *Prog Retin Eye Res* 2007; **26**: 205–238.
42. Bringmann A, Iandiev I, Pannicke T, Wurm A, Hollborn M, Wiedemann P *et al.* Cellular signaling and factors involved in Müller cell gliosis: neuroprotective and detrimental effects. *Prog Retin Eye Res* 2009; **28**: 423–451.
43. Harada C, Mitamura Y, Harada T. The role of cytokines and trophic factors in epiretinal membranes: involvement of signal transduction in glial cells. *Prog Retin Eye Res* 2006; **25**: 149–164.
44. Guo X, Harada C, Namekata K, Kikushima K, Mitamura Y, Yoshida H *et al.* Effect of geranylgeranylacetone on optic neuritis in experimental autoimmune encephalomyelitis. *Neurosci Lett* 2009; **462**: 281–285.
45. Haddadin RI, Oh DJ, Kang MH, Filippopoulos T, Gupta M, Hart L *et al.* SPARC-null mice exhibit lower intraocular pressures. *Invest Ophthalmol Vis Sci* 2009; **50**: 3771–3777.

UNCORRECTED PROOF

NPG.CDD.CDD201062

Dock3 induces axonal outgrowth by stimulating membrane recruitment of the WAVE complex

Kazuhiko Namekata[a], Chikako Harada[a,b], Choji Taya[c], Xiaoli Guo[a], Hideo Kimura[d], Luis F. Parada[b], and Takayuki Harada[a,b,1]

[a]Department of Molecular Neurobiology, Tokyo Metropolitan Institute for Neuroscience, Fuchu, Tokyo 183-8526, Japan; [b]Department of Developmental Biology and Kent Waldrep Foundation Center for Basic Research on Nerve Growth and Regeneration, University of Texas Southwestern Medical Center, Dallas, TX 75390; [c]Department of Laboratory Animal Science, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo 156-8506, Japan; and [d]Department of Molecular Genetics, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8502, Japan

Edited by Thomas C. Südhof, Stanford University School of Medicine, Palo Alto, CA, and approved March 16, 2010 (received for review December 18, 2009)

Atypical Rho-guanine nucleotide exchange factors (Rho-GEFs) that contain Dock homology regions (DHR-1 and DHR-2) are expressed in a variety of tissues; however, their functions and mechanisms of action remain unclear. We identify key conserved amino acids in the DHR-2 domain that are critical for the catalytic activity of Dock-GEFs (Dock1–4). We further demonstrate that Dock-GEFs directly associate with WASP family verprolin-homologous (WAVE) proteins through the DHR-1 domain. Brain-derived neurotrophic factor (BDNF)-TrkB signaling recruits the Dock3/WAVE1 complex to the plasma membrane, whereupon Dock3 activates Rac and dissociates from the WAVE complex in a phosphorylation-dependent manner. BDNF induces axonal sprouting through Dock-dependent Rac activation, and adult transgenic mice overexpressing Dock3 exhibit enhanced optic nerve regeneration after injury without affecting WAVE expression levels. Our results highlight a unique mechanism through which Dock-GEFs achieve spatial and temporal restriction of WAVE signaling, and identify Dock-GEF activity as a potential therapeutic target for axonal regeneration.

Dock family proteins | brain-derived neurotrophic factor | Fyn | axonal regeneration | optic nerve

The Rho-family GTPases (Rho-GTPases, including Rac1, Cdc42, and RhoA), which are best known for their roles in regulating the actin cytoskeleton, have been implicated in a broad spectrum of biological functions, such as cell motility and invasion, cell growth, cell survival, cell polarity, clearance of apoptotic cells, membrane protrusion, and axonal guidance (1, 2). Activation signals from Rac1 and Cdc42 are relayed to the actin-nucleating complex Arp2/3 by a family of proteins that includes Wiskott–Aldrich syndrome protein (WASP) and WASP family verprolin-homologous protein (WAVE) (3, 4). Rho-GTPase activation is mediated by guanine nucleotide exchange factors (GEFs), which share common motifs: the Dbl-homology (DH) domain, which mediates nucleotide exchange (5), and the pleckstrin homology (PH) domain, which targets proteins to membranes and mediates protein–protein interactions (6). Dock1 (Dock180)–related proteins are a new family of Rho-GEFs that lack the DH/PH domains. Instead, Dock family proteins are characterized by two evolutionarily conserved protein domains, termed Dock homology regions 1 and 2 (DHR-1 and DHR-2, respectively) (7). However, the precise functions of the DHR domains are poorly understood. In mammals, there are 11 Dock1-related proteins (Dock1–11). We previously reported that one of the new Rho-GEFs, Dock3, also known as MOCA (modifier of cell adhesion protein), is specifically expressed in the central nervous system (CNS) and induces membrane spreading by activating Rac1 (8).

Neurotrophins are a small family of evolutionarily well-conserved neuropeptides that function in neural cell survival, development, and vertebrate CNS function (9, 10). Neurotrophins, such as brain-derived neurotrophic factor (BDNF), bind to two classes of receptors, the Trk receptor tyrosine kinase family (TrkA, TrkB, TrkC) and the low-affinity receptor p75 ($p75^{NTR}$), leading to complex functional interactions (11, 12). Recent studies have demonstrated that neurotrophins play important roles during gastrulation, in the differentiation of hepatic stellate cells, and in neurulation, through the regulation of Rho-GTPases (9, 13, 14). Considering their relatively ubiquitous expression patterns, it is conceivable that Dock family members, in combination with neurotrophins, could be involved in the development and function of a variety of organs (15–17).

Here, we report that the atypical Rho-GEFs Dock1–4 share key amino acids within the DHR-2 domain that are critical for catalytic activity, and furthermore, that they bind directly to WAVE proteins through the DHR-1 domain. Moreover, we provide both in vitro and in vivo evidence that neuron-specific Dock3 plays a critical role in the membrane trafficking of WAVE proteins and also participates in axonal outgrowth in the adult CNS as an essential downstream component of BDNF-TrkB signaling.

Results

Identification of Critical Residues Involved in GEF Catalytic Activity. To identify residues critical for Rac1 activation, we constructed several Dock3 DHR-2 domain deletion mutants (Fig. 1*A*) and measured their catalytic activity with a GST-CRIB assay (Fig. 1*B*). All of the deletion mutants failed to activate Rac1 (Fig. 1*B*), indicating that amino acids 1358–1375 are required for Dock3-mediated GEF activity. We next introduced single alanine mutations into each of the 18 DHR-2 domain amino acids within full-length Dock3 and found that mutation at F1359, Y1360, G1361, Y1373, or V1374 completely abolished Rac1 activation (Fig. 1*C*) without affecting its ability to interact with Rac1 (Fig. 1*D*). Because the DHR-2 domain is highly conserved among Dock1–4 (Fig. 1*A*), the five single alanine substitutions corresponding to those found in Dock3 were introduced into Dock1, Dock2, and Dock4. All of the mutations drastically reduced Rac1 activation (Fig. S1), demonstrating that these five amino acids of the DHR-2 domain are critical for GEF catalytic activity in all Rac-specific Dock family members.

Dock3 Regulates Axonal Outgrowth. To evaluate whether Dock3 induces axonal outgrowth, we transfected primary cultured hippocampal neurons with plasmid encoding Dock3. Overexpression of Dock3 significantly stimulated axonal outgrowth compared with the control (Fig. 2*A* and *B*). As neurotrophic factors such as BDNF may also regulate Rac1 activation (18), we next examined whether Dock3 and BDNF have a synergistic effect on axonal outgrowth. Overexpression of wild-type (WT) Dock3 increased BDNF-mediated

Author contributions: K.N. and T.H. designed research; K.N., C.H., C.T., and X.G. performed research; K.N., C.T., H.K., and L.F.P. contributed new reagents/analytic tools; K.N., C.H., X.G., L.F.P., and T.H. analyzed data; and K.N., L.F.P., and T.H. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

[1]To whom correspondence should be addressed. E-mail: harada-tk@igakuken.or.jp.

This article contains supporting information online at www.pnas.org/cgi/content/full/0914514107/DCSupplemental.



Fig. 1. Identification of residues critical for the catalytic activity of Dock family members. (*A*) Domain organization and sequence alignments of Dock1–4. (*B*) (*Left*) Cos-7 cells were transfected with Dock3 deletion mutants. Lysates were subjected to a GST-CRIB assay. (*Right*) Quantitation of GTP-Rac. (*C*) Cos-7 cells were transfected with the indicated alanine-substitution mutants of Dock3. Lysates were subjected to a GST-CRIB assay. (*D*) Cos-7 cells were transfected with the indicated alanine-substitution mutants of Dock3. Lysates were incubated with GST-Rac and glutathione-Sepharose. Bound proteins were subjected to immunoblot analysis with anti-Dock3 antibody. (*Lower*) Coomassie Brilliant Blue (CBB) staining of GST-fusion proteins used in this experiment.



Fig. 2. Dock3 enhances BDNF-mediated axonal growth. (*A*) Hippocampal neurons were transfected with Dock3 and cultured in the presence or absence of BDNF for 3 days. (Scale bar, 20 μm.) (*B*) Hippocampal neurons transfected and treated as shown at the *x* axis were fixed at 3 days in vitro, and axon length was measured. $n = 30$ per experimental condition. Data are mean ± SEM of three independent experiments. $*P < 0.05$, $**P < 0.01$. (*C*) Expression of Dock3 in retinal explant cultures. (*Upper*) Dock3 expression in growth cones (arrows). (*Lower*) High magnification of growth cones. Arrowheads indicate Dock3 recruitment to plasma membrane after BDNF treatment. (Scale bars, 50 μm in upper and 10 μm in lower.) (*D*) Ratio of growth cones in which Dock3 was recruited to plasma membrane. Data are mean ± SEM; $n = 20$ for each experimental condition. $*P < 0.01$.

axonal outgrowth (Fig. 2 *A* and *B*), whereas Dock3 siRNA for downregulating endogenous Dock3 inhibited the effect of BDNF (Fig. 2*B*). Combinatorial siRNA to Dock1–4 decreased the baseline axon length (Fig. 2*B*). In addition, $Dock3^{Y1360A}$ and $Dock3^{Y1373A}$ also inhibited the effect of BDNF (Fig. 2*B*). BDNF-mediated axonal outgrowth and Rac1 activation were observed in cultured neurons from WT and $p75^{NTR}$ KO mice, but not from TrkB KO mice (Fig. S2). Trk receptor-specific inhibitor K252a and overexpression of dominant-negative Rac1 (Rac1 N17) suppressed BDNF-mediated axonal outgrowth (Fig. S2). Furthermore, we found that Dock3 is expressed in retinal ganglion cells (RGCs) and has a synergistic effect with BDNF on axonal outgrowth in cultured RGCs (Fig. S3). In retinal explant cultures, Dock3 protein was concentrated in growth cones (arrows in Fig. 2*C*) and was diffuse in cytoplasm (control panel in Fig. 2*C*). However, BDNF treatment rearranged Dock3 staining to the cell periphery (arrowheads in Fig. 2 *C* and *D*). These data demonstrate that Dock3 act in concert, upstream of Rac1, to promote axonal outgrowth through TrkB receptor signaling.

Interaction of Dock3 and Fyn at the Growth Cone. One consequence of the presence of BDNF in neurons is the activation of Fyn and its association with the TrkB receptor (19). Indeed, BDNF induced Fyn activation via phosphorylation at Y416 in primary cultured hipocampal neurons (Fig. 3*A*). Because the proline-rich motif of Dock3 binds to SH3 domain-containing proteins (8), we next examined whether Fyn, which also possesses an SH3 domain, interacts with Dock3. A GST-fusion protein of the proline-rich Dock3 C terminus (amino acids 1773–2028) coprecipitated Fyn in lysates of mouse brain as well as Fyn-transfected Cos-7 cells (Fig. 3*B*). In addition, a His-tag pull-down assay in Cos-7 cells transfected with His-tagged Dock3 together with WT Fyn, constitutively active Fyn^{Y528F}, or ΔSH3 Fyn^{Y528F} (20), confirmed the SH3 domain requirement and preferential binding to the active form of Fyn (Fig. 3*C*). In contrast, Fyn failed to bind to Elmo (21), which interacts with Dock1–4 and enhances their GEF activities (Fig. S4). Thus, the BDNF/TrkB-dependent activation and association with Fyn is specific. Consistent with the activated TrkB association with Fyn and interaction with Dock3, Dock3 translocated from cytosol to the membrane in SY5Y cells transfected with TrkB and Fyn^{Y528F} in the presence of BDNF, but not in cells transfected with TrkB and ΔSH3 Fyn^{Y528F} (Fig. 3*D*). In addition, BDNF-treated retinal explants exhibit colocalization of Dock3 and Fyn at the peripheral regions of the growth cone (arrowheads in Fig. 3*E*). These results are consistent with a model whereby BDNF-TrkB signaling induces the formation of a protein complex of Dock3 at the plasma membrane (Fig. 2 *C* and *D*). We further constructed a mutant Dock3 lacking Fyn binding domain (Δ1773–



Fig. 3. BDNF induces direct binding of Dock3 and Fyn in the growth cone. (*A*) Hippocampal neurons were transfected with WT Fyn and stimulated with BDNF for the indicated times. Lysates were subjected to immunoblot analysis with anti-Fyn^{pY416} or total Fyn antibodies. (*Lower*) expression levels of phosphorylated Fyn. Data are mean ± SEM of three independent experiments. $*P < 0.05$. (*B*) Lysates from mouse brain and Cos-7 cells transfected with WT Fyn were incubated with a GST-fusion protein of the Dock3 proline-rich domain. Bound proteins were subjected to immunoblot (IB) analysis with an anti-Fyn antibody. (*Lower*) Coomassie Brilliant Blue (CBB) staining of the GST-fusion proteins used in this experiment. (*C*) (*Left*) Schematic diagram of the WT and mutant Fyn constructs used in this assay. (*Right*) Lysates from Cos-7 cells transfected as shown at the top of the images were subjected to a His-tag pull-down assay with antibodies against Fyn and Dock3. (*D*) SY5Y cells were transfected with TrkB and Fyn^{Y528F} or ΔSH3 Fyn^{Y528F} and treated with BDNF. Arrowheads indicate colocalization of Dock3 (green) and WAVE1 (red) at the peripheral region. Arrow indicates a nontransfected cell. (Scale bar, 20 μm.) (*E*) Colocalization of endogenous Dock3 (green) and Fyn (red) in growth cone of retinal explant cultures after BDNF treatment. (Scale bar, 10 μm.) (*F*) Hippocampal neurons transfected and treated as shown at the *x* axis were fixed at 3 days in vitro and axon length measured. $n = 30$ for each experimental condition. Data are mean ± SEM of three independent experiments. $*P < 0.05$.

2028) and found that this mutant failed to stimulate BDNF-induced axonal outgrowth (Fig. 3*F*).

Direct Interaction of Dock3 and WAVE Proteins. Because WAVE proteins play a major role in Rac-induced actin dynamics, including actin nucleation and polymerization (3, 4), we speculated that they could be involved in Dock3-mediated axonal outgrowth. To investigate the possibility that WAVE1 can directly bind to Dock3, we performed a His-tag pull-down assay using WT Dock3 or several Dock3 truncation mutants. We found that Dock3 directly bound to WAVE1 at the DHR-1 domain (Fig. 4*A*). We next constructed a mutant that lacks the DHR-1 domain (ΔDHR-1) and determined that this mutant also failed to bind to WAVE1 (Fig. 4*B*). We further confirmed that the DHR-1 domain of Dock3 was required to mediate WAVE1–3 binding (Fig. 4*C*). Indeed, this interaction between Dock and WAVE proteins can be generalized (Fig. S5). In addition, we



Fig. 4. Phosphorylation of Dock3 regulates its interaction with WAVE. (*A*) (*Left*) schematic diagram of the WT and mutant Dock3 constructs used in this assay. (*Right*) Lysates from Cos-7 cells transfected as shown at the top of the images were subjected to a His-tag pull-down assay with antibodies against WAVE1 and Dock3. (*B*) Lysates from Cos-7 cells transfected as shown at the top of the images were subjected to a His-tag pull-down assay with antibodies against WAVE1 and Dock3. (*C*) Lysates from Cos-7 cells transfected as shown at the top of the images were subjected to a His-tag pull-down assay with antibodies against myc-tag, WAVE1, WAVE2, and WAVE3. (*D*) Hippocampal neurons transfected and treated as shown at the *x* axis were fixed at 3 days in vitro, and axon length was measured. $n = 30$ for each experimental condition. Data are mean ± SEM of three independent experiments. $*P < 0.05$. (*E*) (*Left*) Schematic diagram of the WT and mutant WAVE1 constructs used in this assay. (*Right*) Lysates from Cos-7 cells transfected as shown at the top of the images were subjected to a His-tag pull-down assay with antibodies against Dock3 and WAVE1. (*F*) SY5Y cells transfected with WT Dock3 or F-Dock3 were probed with antibodies against WAVE1 (red) and Dock3 (green). Arrowheads indicate WAVE1 protein at the peripheral region. The arrow indicates a nontransfected cell. (Scale bar, 10 μm.) (*G*) Lysates from Cos-7 cells transfected with WT Dock3 or F-Dock3 were subjected to immunoblot analysis with an anti-Dock3 antibody. Arrow indicates phosphorylated Dock3. (*H*) (*Upper*) Relative expression levels of phosphorylated Dock3 to total Dock3. (*Lower*) Lysates from Cos-7 cells transfected as shown at the bottom of the images were subjected to a His-tag pull-down assay. Bound and unbound proteins were subjected to immunoblot analysis with an anti-Dock3 antibody. Arrow indicates phosphorylated Dock3.

demonstrated that ΔDHR-1 failed to stimulate BDNF-induced axonal outgrowth in hippocampal neurons (Fig. 4*D*). We next prepared both WT and two mutant forms of WAVE1 constructs and found that one mutant that lacks the WAVE-homology domain (WHD) failed to bind to WT Dock3 (Fig. 4*E*). Based on the preceding data, we hypothesized that membrane targeting of Dock3 may regulate the intracellular localization of WAVE. To assess this possibility, we transfected SY5Y cells with WT Dock3 and subjected them to immunocytochemistry. Overexpression of WT Dock3 did not change the intracellular localization of WAVE1 (Fig. 4*F*). In contrast, overexpression of farnesylated Dock3 (F-Dock3, a membrane-targeted form of Dock3) translocated WAVE1 from the cytoplasm to the peripheral regions (arrowheads in Fig. 4*F*). Taken together, these results suggest that the DHR-1 domain of Dock family proteins mediates direct binding to WAVE proteins leading to colocalization at the cell periphery and axonal outgrowth.

We also found a strong enhancement of the Dock3 upper mobility band (arrow in Fig. 4*G*) in Cos-7 cells transfected with F-Dock3 but not with WT Dock3 (26 ± 6% and 2 ± 1% of total Dock3, respectively). Consistent with the upper mobility band representing a phosphorylated form of Dock3, the mobility shift was eliminated by phosphatase treatment (Fig. 4*G*). We next examined the effect of Dock3 phosphorylation on its ability to bind WAVE. Cos-7 cells were transfected with His-tagged WAVE1 and F-Dock3 and subjected to a pull-down assay. Immunoblot analysis revealed that WAVE1 binds to the unphosphorylated form of Dock3 more effectively than to the phosphorylated form (Fig. 4*H*). Thus, the Dock3/WAVE1 complex may dissociate upon Dock3 phosphorylation, leading to spatially restricted actin dynamics through WAVE signaling.

Promoting Axonal Outgrowth in Adult CNS by Modulating Dock3 Activity. To investigate the effects of Dock3 in vivo, we generated transgenic (Tg) mice overexpressing WT Dock3 under control of the actin promoter. Tg mice showed high expression levels of Dock3 in many tissues, especially in the optic nerve (~5.6-fold) and retina (~2.3-fold; Fig. S6*A*), but the structure of such tissues were normal (Fig. S6 *B* and *C*). Therefore, we prepared retinal explants from WT and Tg mice and examined the effect of Dock3 on axon length. Quantitative analysis revealed that axon length was clearly greater in Tg mice than in their WT littermates (Fig. 5*A*). Furthermore, Dock3 and BDNF exerted synergistic effects on axonal growth, as observed in vitro (Fig. 2 *A* and *B*). These results suggest that axonal outgrowth is promoted in Dock3 Tg mice. To explore this possibility, we used the optic nerve microcrush model and investigated the extent of axonal outgrowth 2 weeks after injury by staining with GAP43 antibody (22). WT mice subjected to nerve crush showed >40 axons extending 200 μm from the injury site, and half this number extended 500 μm. In contrast, Tg mice had, on average, >80 axons extending 200 μm and >60 axons extending 500 μm beyond the lesion site (Fig. 5*B*). Immunohistochemical analysis of Dock3 and WAVE1 in injured optic nerves revealed that their coexpression was hardly detectable in WT mice, but was clearly increased in regenerating axons in Tg mice (Fig. 5*C*). We next examined the levels of Dock3 and WAVE1 proteins in optic nerves by immunoblotting (Fig. S7). Dock3 protein was reduced in injured WT optic nerves (decreased to ~10% of control), but this reduction was less severe in Tg mice. In both WT and Tg mice, WAVE1 protein was less abundant after the injury (reduced to ~60%). Whereas in the membrane fraction of crushed optic nerves, Dock3 and WAVE1 expression levels in Tg mice were significantly higher than WT mice (Fig. 5*D* and *E*). We also examined the expression of TrkB and Fyn in injured optic nerves, but their expression levels in Tg mice were not significantly altered compared with those in WT mice (Fig. S8). Thus, overexpression of Dock3 does not affect the expression levels of its binding partners, but may induce axonal outgrowth through effective membrane recruitment of WAVE1.



Fig. 5. Overexpression of Dock3 induces axonal regeneration in vivo. (*A*) (*Upper*) Retinal explants from WT and Dock3 Tg mice cultured in the presence or absence of BDNF were fixed and labeled with phalloidin at 2 days in vitro. (*Lower*) Axon length was measured and quantified. Data are mean ± SEM, $n > 80$ axons for each group. $^*P < 0.05$. (Scale bar, 100 μm.) (*B*) (*Upper*) GAP43-labeled axons in the optic nerve proximal to the injury site (dotted line) 2 weeks after nerve surgery. Arrowheads indicate regenerating axons. (*Lower*) Regenerating axons from lesion site were measured and quantified. Data are mean ± SEM for six independent experiments. $^*P < 0.05$. (Scale bar, 50 μm.) (*C*) Immunostaining of the optic nerves proximal to the injury site (dotted line). Arrowheads indicate colocalization of Dock3 (green) and WAVE1 (red) in the regenerating axons. (Scale bar, 20 μm.) (*D*) Immunoblot analysis of Dock3 and WAVE1 in the membrane fraction of optic nerve 2 weeks after nerve surgery. (*E*) Expression levels of Dock3 and WAVE1 in the membrane fraction of normal and injured optic nerves were quantified. Data are presented as means ± SEM of three independent experiments. $^*P < 0.05$.

Discussion

In the present study, we found that Dock1–4, which are atypical members of the Rho-GEF family, share several conserved amino acids in their DHR-2 domains that are required for GEF activity. In addition, Dock1–4 bind directly to WAVE1–3 via their DHR-1 domains, and this is disrupted when Dock1–4 become phosphorylated. We further showed that Dock3 forms a protein complex with Fyn and WAVE1 at the plasma membrane downstream of TrkB. Finally, we demonstrated that overexpression of Dock3 increases WAVE1 expression levels in the plasma membrane



Fig. 6. Proposed role of Dock3 in BDNF-mediated axonal outgrowth. BDNF-TrkB signaling induces Fyn phosphorylation and stimulates membrane recruitment of the Dock3/WAVE complex. Dock3 is then able to activate Rac-GDP (inactive form). Rac-GTP (active form) and WAVE are dissociated from phosphorylated Dock3 and stimulate actin reorganization, leading to axonal outgrowth.

and promotes optic nerve regeneration in vivo. Taken together, our results suggest a unique mechanism for axonal outgrowth through which Dock-GEFs recruit WAVE proteins to specific sites within cells and induce spatially restricted actin dynamics in the CNS (Fig. 6).

BDNF/TrkB signaling is important for a variety of CNS developmental processes including synaptic pruning (23, 24). In addition, Rho-GTPase signaling can affect both spine structure and synaptic function (25, 26). In this study, we found that treatment of hippocampal neurons with BDNF enhances Rac1 activation and neurite outgrowth. It is therefore possible that Dock-GEFs mediate multiple BDNF/TrkB functions, including the establishment of long-term potentiation. On the other hand, loss of Dock3 leads to sensorimotor impairments and structural changes, including axonal swellings, but had no effects on life span or fertility (15). These relatively mild phenotypes are reasonable, considering the redundant catalytic sequences found in the DHR-2 domains of Dock1–4. Recent studies have revealed that a Val66Met polymorphism in human BDNF is involved in the pathogenesis of attention-deficit/hyperactivity disorder (ADHD) (27–29). Interestingly, a pericentric inversion breakpoint in the *DOCK3* gene has been described in ADHD patients (30). Thus, further study is required to determine the full implications of the Dock-GEFs in BDNF-associated development, adult physiology, and disease.

Dock3 overexpression induced optic nerve regeneration after injury without affecting expression levels of its binding partners. For example, WAVE1 expression level after optic nerve injury was decreased to ~60% in both WT and Dock3 Tg mice. However, WAVE1 expression was increased in the membrane fraction and was coexpressed with Dock3 in the regenerating axons. Thus, the tight regulation of Rac1-GDP/Rac1-GTP cycling and effective membrane recruitment of WAVE proteins by Dock3, rather than prolonged activation of Rac1 or WAVE proteins (31–33), may be required for axonal growth via actin polymerization. Our present findings support the notion that neurons have to intrinsically upregulate the necessary growth-associated molecules to extend an axon (34, 35). On the other hand, recent studies have shown that glial scarring and several myelin inhibitors block axonal growth following CNS injury (35, 36). Thus, overexpression of Dock-GEFs may have a synergistic effect in combination with suppression of glial scarring and myelin-associated inhibitory signaling.

Lack of axonal regeneration in the adult CNS is one of the most important issues to be resolved in various neurodegenerative disorders. For example, glaucoma is characterized by a slow progressive degeneration of optic nerve axons. Thus, Dock/WAVE complexes and their related binding partners may be possible therapeutic targets in multiple forms of glaucoma that otherwise lead to severe visual impairment. We are presently investigating these issues by crossing Dock3 Tg mice with glutamate transporter knockout mice, which are the first animal models of normal tension glaucoma (37). Thus, further studies are required to explore the full potential of Dock-GEFs that could be used for effective regeneration therapy.

Materials and Methods

Experimental Animals. Experiments were performed using p75^{NTR} knockout and TrkB × hGFAP-cre knockout (TrkB KO) mice in accordance with the Tokyo Metropolitan Institute for Neuroscience *Guidelines for the Care and Use of Animals*. The TrkB deletion was confirmed in the hippocampus of the TrkB KO mice (23). A Tg construct containing the CAG promoter, *Dock3* coding sequence (GenBank accession no. NM_153413), and a polyadenylation signal was used to generate Dock3 Tg mice. The founder mice were generated by injecting the transgene into fertilized C57BL/6 eggs. RGCs were retrogradely labeled with Fluoro-Gold (Fluorochrome) as previously described (38).

Cell Culture. Primary cultured hippocampal neurons (39) and retinal explants (22) were prepared from E16 mice. In some experiments, they were stimulated with BDNF (5 or 50 ng/mL; Alomone Labs).

Plasmids and siRNA Transfection. WAVE1–3 plasmids were provided by T. Takenawa (40). Elmo2 and GST-CRIB plasmids were provided by H. Kato and M. Negishi (21). Rac and Dock1 plasmids were provided by M. Matsuda (41). Dock3, Fyn, and WAVE1 fragments were PCR-amplified from full-length cDNAs and expressed as His-tagged proteins. Alanine substitutions were generated with the PrimeSTAR Mutagenesis Basal Kit (Takara). RNA oligomers containing 21 nucleotides for RNA interference for Dock1–4 were synthesized in the sense and antisense directions (Dock1: 5′-GGAAGUCACCACAACGCU UUU-3′; Dock2: 5′-GCAUCUCA CGCUACAGAUUUU-3′; Dock3: 5′-GCAGAUCA GUGAACGGUUUU-3′; Dock4: 5′-GCAAGAGUGUGGCCAGAAAUU-3′) (JBioS). Transfection of siRNAs and plasmids was performed using the Nucleofector System (Amaxa) or Lipofectamine Plus (Invitrogen).

Pull-Down Assay. His-tagged proteins were purified from Cos-7 cell lysates with TALON resin (BD Biosciences) for 20 min at 4 °C with gentle agitation. The protein levels of Rac-GTP were measured by affinity precipitation using the GST-CRIB of PAK1. Bacterial GST-fusion proteins were incubated with lysates from Cos-7 cells or mouse brains. The precipitated samples were subjected to SDS-PAGE followed by immunoblot analysis (8) with the following antibodies: Fyn, phospho-Fyn (Tyr416) and WAVE1 were obtained from BD Biosciences; WAVE2 and WAVE3 were obtained from Santa Cruz.

Immunostaining. SY5Y cells, retinal explants, sections of retina, and optic nerves were incubated with anti-Dock3 (1:200), anti-WAVE1 (1:200), and anti-GAP43 (1:1,000; Chemicon) antibodies. Cy2-conjugated donkey antirabbit IgG or Cy3-conjugated donkey antimouse IgG were used as secondary antibodies. F-actin was visualized with rhodamine-labeled phalloidin (Invitrogen).

Optic Nerve Injury. Mice were anesthetized with sodium pentobarbital before optic nerve crush. Optic nerves were exposed intraorbitally and crushed about 0.5–1.0 mm from the posterior pole of the eyeball with fine surgical forceps for 5 s (22). Fourteen days after surgery, axonal outgrowth was quantified by counting GAP43-positive axons that crossed a virtual line parallel to the lesion site at 200 μm and 500 μm distal to the lesion site. Protein expression levels in the lesion site were measured by immunoblot analysis with antibodies against Dock3 and WAVE1–3. Membrane fraction was prepared as previously described (42).

Image Analysis and Statistics. To measure axon length, the longest axon of each neuron was traced and calculated using National Institutes of Health ImageJ (version 1.38). Approximately 50 neurons with axons were scanned using a DP70 CCD camera (Olympus). Data are presented as mean ± SEM. For statistical analyses, a two-tailed Student's *t* test was used. Values of $P < 0.05$ were regarded as statistically significant.

ACKNOWLEDGMENTS. We are grateful to T. Takenawa (Kobe University) and H. Kato, M. Negishi, and M. Matsuda (Kyoto University) for reagents. We thank A. Kimura, K. Nakamura, and K. Nishimura for technical assistance, and R. McKay for comments on the manuscript. This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to K.N., C.H., and T.H.); Ministry of Health, Labour, and Welfare of Japan; Uehara Memorial Foundation; Naito Foundation; Suzuken Memorial Foundation; Daiwa Securities Health Foundation; Takeda Science Foundation; and Japan Medical Association (to T.H.).

1. Iwasato T, et al. (2007) Rac-GAP alpha-chimerin regulates motor-circuit formation as a key mediator of EphrinB3/EphA4 forward signaling. *Cell* 130:742–753.
2. Schmidt A, Hall A (2002) Guanine nucleotide exchange factors for Rho GTPases: Turning on the switch. *Genes Dev* 16:1587–1609.
3. Goley ED, Welch MD (2006) The ARP2/3 complex: An actin nucleator comes of age. *Nat Rev Mol Cell Biol* 7:713–726.
4. Takenawa T, Suetsugu S (2007) The WASP-WAVE protein network: Connecting the membrane to the cytoskeleton. *Nat Rev Mol Cell Biol* 8:37–48.
5. Cerione RA, Zheng Y (1996) The Dbl family of oncogenes. *Curr Opin Cell Biol* 8:216–222.
6. Lemmon MA, Ferguson KM (2000) Signal-dependent membrane targeting by pleckstrin homology (PH) domains. *Biochem J* 350:1–18.
7. Côté JF, Vuori K (2002) Identification of an evolutionarily conserved superfamily of DOCK180-related proteins with guanine nucleotide exchange activity. *J Cell Sci* 115: 4901–4913.
8. Namekata K, Enokido Y, Iwasawa K, Kimura H (2004) MOCA induces membrane spreading by activating Rac1. *J Biol Chem* 279:14331–14337.
9. Guan KL, Rao Y (2003) Signalling mechanisms mediating neuronal responses to guidance cues. *Nat Rev Neurosci* 4:941–956.
10. Harada T, Harada C, Parada LF (2007) Molecular regulation of visual system development: More than meets the eye. *Genes Dev* 21:367–378.
11. Harada T, et al. (2000) Modification of glial-neuronal cell interactions prevents photoreceptor apoptosis during light-induced retinal degeneration. *Neuron* 26: 533–541.
12. Segal RA (2003) Selectivity in neurotrophin signaling: Theme and variations. *Annu Rev Neurosci* 26:299–330.
13. Knapp D, Messenger N, Ahmed Rana A, Smith JC (2006) Neurotrophin receptor homolog (NRH1) proteins regulate mesoderm formation and apoptosis during early Xenopus development. *Dev Biol* 300:554–569.
14. Passino MA, Adams RA, Sikorski SL, Akassoglou K (2007) Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR. *Science* 315:1853–1856.
15. Chen Q, et al. (2009) Loss of modifier of cell adhesion reveals a pathway leading to axonal degeneration. *J Neurosci* 29:118–130.
16. Kunisaki Y, et al. (2006) DOCK2 is a Rac activator that regulates motility and polarity during neutrophil chemotaxis. *J Cell Biol* 174:647–652.
17. Laurin M, et al. (2008) The atypical Rac activator Dock180 (Dock1) regulates myoblast fusion in vivo. *Proc Natl Acad Sci USA* 105:15446–15451.
18. Miyamoto Y, Yamauchi J, Tanoue A, Wu C, Mobley WC (2006) TrkB binds and tyrosine-phosphorylates Tiam1, leading to activation of Rac1 and induction of changes in cellular morphology. *Proc Natl Acad Sci USA* 103:10444–10449.
19. Pereira DB, Chao MV (2007) The tyrosine kinase Fyn determines the localization of TrkB receptors in lipid rafts. *J Neurosci* 27:4859–4869.
20. Davidson D, Chow LM, Fournel M, Veillette A (1992) Differential regulation of T cell antigen responsiveness by isoforms of the src-related tyrosine protein kinase p59fyn. *J Exp Med* 175:1483–1492.
21. Katoh H, Negishi M (2003) RhoG activates Rac1 by direct interaction with the Dock180-binding protein Elmo. *Nature* 424:461–464.
22. Fischer D, He Z, Benowitz LI (2004) Counteracting the Nogo receptor enhances optic nerve regeneration if retinal ganglion cells are in an active growth state. *J Neurosci* 24:1646–1651.
23. Luikart BW, et al. (2005) TrkB has a cell-autonomous role in the establishment of hippocampal Schaffer collateral synapses. *J Neurosci* 25:3774–3786.
24. Zhou Z, et al. (2006) Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. *Neuron* 52: 255–269.
25. Nakayama AY, Harms MB, Luo L (2000) Small GTPases Rac and Rho in the maintenance of dendritic spines and branches in hippocampal pyramidal neurons. *J Neurosci* 20:5329–5338.
26. Tashiro A, Yuste R (2004) Regulation of dendritic spine motility and stability by Rac1 and Rho kinase: Evidence for two forms of spine motility. *Mol Cell Neurosci* 26: 429–440.
27. Egan MF, et al. (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell* 112:257–269.
28. Friedel S, et al. (2005) Mutation screen of the brain derived neurotrophic factor gene (BDNF): Identification of several genetic variants and association studies in patients with obesity, eating disorders, and attention-deficit/hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet* 132B:96–99.
29. Kent L, et al. (2005) Association of the paternally transmitted copy of common Valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene with susceptibility to ADHD. *Mol Psychiatry* 10:939–943.
30. de Silva MG, et al. (2003) Disruption of a novel member of a sodium/hydrogen exchanger family and DOCK3 is associated with an attention deficit hyperactivity disorder-like phenotype. *J Med Genet* 40:733–740.
31. Kawano Y, et al. (2005) CRMP-2 is involved in kinesin-1-dependent transport of the Sra-1/WAVE1 complex and axon formation. *Mol Cell Biol* 25:9920–9935.
32. Luo L, Jan LY, Jan YN (1997) Rho family GTP-binding proteins in growth cone signalling. *Curr Opin Neurobiol* 7:81–86.
33. Zipkin ID, Kindt RM, Kenyon CJ (1997) Role of a new Rho family member in cell migration and axon guidance in C. elegans. *Cell* 90:883–894.
34. Bouquet C, Nothias F (2007) Molecular mechanisms of axonal growth. *Adv Exp Med Biol* 621:1–16.
35. Hannila SS, Filbin MT (2008) The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury. *Exp Neurol* 209:321–332.
36. Cafferty WB, McGee AW, Strittmatter SM (2008) Axonal growth therapeutics: Regeneration or sprouting or plasticity? *Trends Neurosci* 31:215–220.
37. Harada T, et al. (2007) The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma. *J Clin Invest* 117:1763–1770.
38. Harada C, et al. (2006) Role of apoptosis signal-regulating kinase 1 in stress-induced neural cell apoptosis in vivo. *Am J Pathol* 168:261–269.
39. Yoshimura T, et al. (2005) GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. *Cell* 120:137–149.
40. Oda A, et al. (2005) WAVE/Scars in platelets. *Blood* 105:3141–3148.
41. Kiyokawa E, et al. (1998) Activation of Rac1 by a Crk SH3-binding protein, DOCK180. *Genes Dev* 12:3331–3336.
42. Nakamura K, Namekata K, Harada C, Harada T (2007) Intracellular sortilin expression pattern regulates proNGF-induced naturally occurring cell death during development. *Cell Death Differ* 14:1552–1554.

Aberrant Detergent-insoluble EAAT2 Accumulates in Alzheimer's Disease

Running Head: **EAAT2 Aberrantly Accumulates in MCI and AD**

Randall L. Woltjer, MD, PhD [1], Kevin Duerson, PhD [2], Joseph M. Fullmer MD, PhD [3], Paramita Mookherjee, PhD [4], Allison M. Ryan [1], Thomas J. Montine, MD, PhD [4], Jeffrey A. Kaye, MD [5], Joseph F. Quinn, MD [5], Lisa Silbert, MD, MCR [5], Deniz Erten-Lyons, MD [5,6], James B. Leverenz, MD [7], Thomas D. Bird, MD [2,7], David V. Pow, PhD [8], Kohichi Tanaka, MD, PhD [9], G. Stennis Watson, PhD [2,10], & David G. Cook, PhD [2,11] *

1 Department of Pathology, Oregon Health & Sciences Univ., Portland, OR
2 Geriatric Research Education and Clinical Center (GRECC), VA Medical Center (VAPSHCS), Seattle, WA.
3 Department of Pathology, University of Wisconsin, Madison, WI
4 Department of Pathology, University of Washington, Seattle, WA
5 Department of Neurology, Oregon Health & Sciences Univ., Portland, OR
6 Research and Development Service, VA Medical Center, Portland, OR
7 Department of Neurology, University of Washington, Seattle, WA
8 U.Q. Centre for Clinical Research, Royal Brisbane and Women's Hospital, Brisbane, Australia.
9 Laboratory of Molecular Neuroscience, School of Biomedical Science and Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan
10 Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA.
11 Departments of Medicine and Pharmacology, University of Washington, Seattle WA

* To whom correspondence should be address:
David G. Cook, Ph.D.
VA Medical Center
GRECC
1660 S. Columbian Way
Seattle, WA 98108

206-768-5437 (phone)
206-764-2569 (fax)
dgcook@u.washington.edu

Sources of support: Veteran's Affairs Office of Research and Development Medical Research Service (DGC), NIH institutional fellowships to K.D., J.M.F. (T32 AG000258), and to P.M. (T32 AG00057-31). University of Washington Alzheimer's Disease Research Center (AG5036) and the Oregon Alzheimer's Disease Center (5P30AG008017).

Role(s) of authors: Critical input on study design, manuscript preparation and data analyses (RLW, GSW, DGC). Clinical and neuropathological characterization / analyses of subjects and subject tissue samples (RLW, JMF, AMR, TJM, JAK, JFQ, LS, DE-L, JBL, TDB). Contributed essential samples, reagents, and/or technical support in experimental design (KT, DVP). Conducted experiments and provided critical input on manuscript preparation (RLW, KD, DGC, AMR, JMF, PM).

ABSTRACT

Alzheimer's disease (AD) is characterized by deposition of amyloid-β, tau, and other specific proteins that accumulate in detergent-insoluble complexes. AD also involves glutamatergic neurotransmitter system disturbances. EAAT2 is the dominant glutamate transporter in cerebral cortex and hippocampus. We investigated whether accumulation of detergent-insoluble EAAT2 is related to cognitive impairment and neuropathologic changes in AD by quantifying detergent-insoluble EAAT2 levels in hippocampus and frontal cortex of cognitively normal patients, patients with clinical dementia rating (CDR) = 0.5 (mildly impaired), and AD patients. Parkinson's disease (PD) patients served as neurodegenerative disease controls. We found that Triton X-100-insoluble EAAT2 levels were significantly increased in patients with AD compared to controls, while Triton X-100-insoluble EAAT2 levels in CDR=0.5 patients were intermediately elevated between control and AD subjects. Detergent-insolubility of Presenilin-1, a structurally similar protein, did not differ between groups, thus arguing EAAT2 detergent-insolubility was not due to non-specific cellular injury. These findings demonstrate that detergent-insoluble EAAT2 accumulation is a progressive biochemical lesion that corresponds with cognitive impairments and neuropathologic changes in AD. These findings also lend additional support to the idea that dysregulation of the glutamatergic system may play a significant role in AD pathogenesis.

Keywords: SLC1A2, Mild cognitive impairment, Protein aggregation, Oxidative stress, Excitotoxicity